Showing results (421-430 of 577) with videos related to

Sort By:
Pageof 58
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2016
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell LymphomaLuca Ceriani, Maurizio Martelli, Maria K Gospodarowicz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapyMassimiliano Salati, Francesco Caputo, David Cunningham, et al.
Oncotarget|June 11, 2016
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinomaAskar Obulkasim, Bauke Ylstra, Hendrik F van Essen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2022
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancerTiuri E Kroese, Peter S N van Rossum, Magnus Nilsson, et al.
The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.
British Journal of Haematology|November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waitingMaria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Oncotarget|October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trialMatthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.
Pageof 58